EGFR and neoplasm: Specifically, if C797S and T790M mutations are on different chromosomes (in trans), tumor will retain sensitivity to the combination treatment of first- and third-generation inhibitors; while they are on the same chromosome (in cis), EGFR-TKIs alone or in combination are ineffective [108].